Participating in the development of:
In the 1990s, the group of Dr. Sergey Seredenin (an acting member of the Russian Academy of Sciences), successfully developed a neuroprotective compound with a mild anxiolytic effect. This drug was as potent as the existing drugs, but lacking the side effects, attributable to the competitor drugs. This novel compound was developed at the Scientific Research Institute of Pharmacology (named after V. V. Zakusov). This medical product was registered in Russia in 2005 and has since been used for successful treatment of various anxiety disorders, proving its safety and efficacy.
We hypothesized that this drug has a novel mechanism of action. The research has shown that the drug selectively activates sigma receptors in the brain, which play an important role in the neuroprotection. We suggested that the drug may be effective in the treatment and prevention of a number of pathological conditions of the brain, including ischaemic cerebral stroke, Alzheimer’s disease and multiple sclerosis.